Lund, Sweden 26th of June 2025, Phase Holographic Imaging PHI AB ("PHI" or the "Company"), ,a leading provider of advanced holographic imaging solutions, is pleased to announce significant organisational changes to strengthen its global operations.

Håkan Rosvall, currently the President of PHI's US operations, has been appointed the Chief Commercial Officer (CCO) for PHI's global operations. In his new role, Rosvall will oversee the Company's commercial strategy and drive global sales initiatives. Rosvall has been a part of PHI since 2010 and joined the PHI team when the Company had launched its first product - HoloMonitor M3 - and was then responsible for building up the distribution network worldwide. Since then, Rosvall has been in different roles, most recently president of PHI's subsidiary in the USA. Rosvall will start his new position in July 2025 and will relocate back to Sweden to assume his new responsibilities.

Additionally, PHI is excited to announce the appointment of Casey Clark, PhD as the new President of PHI's subsidiary in the USA. Casey will be stationed at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, where he will lead the Company's US operations and clinical research. These organisational changes will take effect on 1 July 2025.

"We are thrilled to have Håkan Rosvall take on the role of Chief Commercial Officer and lead our global commercial efforts," says Patrik Eschricht, CEO of PHI. "His extensive experience and proven track record in the industry make him the ideal candidate to drive our growth and success on a global scale. We also look forward to Casey Clark leading our US operations. We have great faith that his decade of biomedical expertise will push our product forward into new applications."

For more information about PHI, please contact:

Patrik Eschricht, CEO

E-mail: ir@phiab.com

Website: www.phiab.com

About PHI

Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI's current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology - an innovative approach to cell quality evaluation. QPI offers a detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden; Boston, MA; and Winston-Salem, NC.